Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Neuromodulation of Sleep and Mood: A Multimodal Biomarker Study of Non-Invasive Vagal Nerve Stimulation (MOSAIC-VNS) (MOSAIC-VNS)

13 novembre 2026 aggiornato da: Matthew Macaluso, University of Alabama at Birmingham

The purpose of this study is to learn how non-invasive cervical transcutaneous vagus nerve stimulation (ctVNS) - a treatment given by holding a small hand-held device against the right part of your neck (cervical vagus nerve) - affects sleep, heart rhythm, mood, and certain markers in the blood and some genetic material.

The main questions it aims to answer are:

  1. Will ctVNS enhance both subjective and objective sleep continuity and regularity, improve circadian stability, and increase parasympathetic HRV indices compared with the end-of-sham baseline?
  2. Will improvements in HRV and sleep be associated with greater improvement in standardized depression ratings, with treatment effects mediated in part by improvements in sleep and in part by sleep-independent autonomic mechanisms?
  3. Will ctVNS modify the expression of miRNAs related to sleep, stress, inflammation, and neuroplasticity, and baseline or early-change miRNA profiles, combined with physiological data, and may help distinguish responders from non-responders?

This study lasts about 7 weeks.

Participants will be asked to do the following:

Visit 1/ Baseline (in person):

  • Participants will answer questions about their health, mood, and sleep;
  • have their blood pressure and pulse taken;
  • give about 28 mL (about 6 teaspoons) of blood - 20 mL for the research measurements and 8 mL for routine safety blood tests;
  • be fitted with a wrist device that measures your heart rate, physical activity and sleep; and be given the study device with training on how to use it at home.

This visit will last about 2 hours.

Weeks 1-6 (at home):

  • Participants will use the study device (nerve stimulator) twice a day (morning within 1 hour of waking, and evening within 1 hour of your usual bedtime), each use lasting about 2 minutes;
  • Participants will also need to wear the wrist device day and night;
  • Participants will fill out a short sleep diary each morning.

Visit 2/ Week 2 (in person) and Visit 3/ Week 6 (in person):

  • Participants will repeat the questionnaires and interviews from Visit 1;
  • have their blood pressure and pulse taken;
  • give another blood sample of about 20 mL;
  • have the data from their wrist device downloaded.
  • At each in-person visit after visit 1, their study device will be checked and may be exchanged for another device.

This visit will last about 1.5 - 2 hours.

The investigators will call participants on the phone to check-in at Weeks 1, 3, and 5, and a safety call at Week 7. These phone calls will last about 15 minutes.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Major depressive disorder (MDD) and insomnia are highly prevalent, frequently co-occur, and rank among the leading causes of disability worldwide. Up to 80% of people with MDD report significant sleep disturbance, and persistent insomnia predicts higher relapse, poorer treatment response, and greater functional impairment. Autonomic dysregulation, commonly indexed by reduced heart rate variability (HRV), is a shared feature of both conditions and a marker of poor outcome [1], alongside circadian disruption and neuroinflammatory signaling.

Cervical transcutaneous vagus nerve stimulation (ctVNS) engages vagal afferents transcutaneously and may rebalance sympathetic-parasympathetic tone [2,3] and attenuate neuroinflammatory signaling implicated in anxiety and depression [4], with downstream effects on emotion-regulatory circuits and on sleep. Despite this mechanistic plausibility, treatment response to ctVNS remains heterogeneous and mechanistically unclear, and no validated marker identifies who will benefit.

Circulating microRNAs (miRNAs) are stable, accessible post-transcriptional regulators whose peripheral profiles are altered in MDD and may track with diagnosis or relapse risk [5,6]. Preclinical evidence shows that vagus nerve stimulation, which engages the same afferent pathways as ctVNS, modulates stress- and neuroplasticity-related miRNAs (for example, miR-183-3p) [7-9]. Neural-derived exosomes (NDE) isolated from plasma are enriched for signals of neuronal origin and provide a means of interrogating brain-relevant molecular processes from a peripheral blood sample.

Neuromodulation is changing how mental and other central nervous system disorders are treated, but its clinical use is limited by an inability to predict who will respond or why. Three specific gaps slow progress: (1) the pathways linking ctVNS to improvements in sleep and depression remain unclear; (2) no study has combined continuous wearable monitoring with circulating candidate biomarkers to predict response; and (3) the relationship between autonomic change and depression improvement has not been defined.

This study addresses those gaps by combining longitudinal wearable-derived autonomic monitoring, subjective and objective sleep phenotyping, standardized clinical outcomes, and circulating neural-derived exosomal miRNA profiling within a single mechanistic framework. The design separates sleep-mediated from sleep-independent autonomic pathways underlying changes in depression.

A within-subject sham run-in was selected rather than a parallel randomized design because the aim of this pilot is within-subject signal detection and effect-size estimation rather than controlled efficacy testing. The sham run-in establishes a stable, expectancy-adjusted personal baseline and prevents carryover from active stimulation from contaminating that reference. A fixed sham-to-active order partially confounds treatment with time; this limitation is stated explicitly, is mitigated by the end-of-sham anchor and by a group-level autonomic target-engagement check, and is addressed in the planned subsequent randomized, concurrent sham-controlled trial.

Healthy reference participants (Cohort B) are enrolled not as efficacy subjects but to establish normative ranges for HRV, sleep metrics, and candidate miRNA expression, enabling interpretation of disease-related biomarker deviations.

Tipo di studio

Interventistico

Iscrizione (Stimato)

40

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35294
        • University of Alabama at Birmingham (UAB)
        • Investigatore principale:
          • Matthew Macaluso, DO
        • Contatto:
        • Contatto:
        • Sub-investigatore:
          • Justin Thomas, PhD
        • Sub-investigatore:
          • Yogesh Dwivedi, PhD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 50 anni (Adulto)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • To be eligible, participants must meet all of the following criteria:

    1. Adults aged 18 through 50 years, inclusive, at the time of consent.

    2. Able to understand and provide written informed consent in English.

    3. Willing and able to wear a study-provided wrist-worn device continuously for approximately 6 weeks and to complete daily sleep diaries.

    4. Willing and able to self-administer the study device twice daily for 6 weeks and to complete a device use log.

    5. Access to a smartphone compatible with the study wearable platform, or willingness to use a study-provided device.

    6. Regular sleep opportunity of at least 6 hours per 24-hour period.

      Cohort A (symptomatic) - additional inclusion criteria:

    7. Insomnia Severity Index (ISI) total score ≥ 15 at screening and confirmed at Visit 1.

    8. MADRS total score ≥ 20 at screening and confirmed at Visit 1.

    9. Meets DSM-5-TR criteria for insomnia disorder on structured clinical interview.

    10. If receiving psychotropic medication or psychotherapy, the regimen has been stable for at least 6 weeks before Visit 1, and the participant and treating clinician agree it will remain stable through Visit 3.

      Cohort B (healthy reference) - additional inclusion criteria:

    11. ISI total score ≤ 7 and MADRS total score ≤ 8 at screening and confirmed at Visit 1.

    12. No current psychiatric disorder or sleep disorder as established by structured diagnostic interview.

    13. No psychotropic medication use within the prior 30 days.

Exclusion Criteria:

  • Participants meeting any of the following criteria are not eligible:

    1. Night-shift or rotating-shift work within the 30 days before Visit 1, or planned during participation.
    2. Travel across more than two time zones within the 14 days before Visit 1, or planned during participation.
    3. Any contraindication to cervical nVNS, including an implanted cervical electrical or metallic device, cardiac pacemaker or implantable cardioverter-defibrillator, any other implanted electronic device, clinically significant carotid atherosclerosis, prior cervical vagotomy, carotid endarterectomy, or cervical surgery at the application site.
    4. Open wound, skin breakdown, active infection, or a dermatologic condition at the intended application site.
    5. Known or suspected pregnancy, or breastfeeding. Participants of childbearing potential will undergo urine pregnancy testing at screening..
    6. Clinically significant cardiac arrhythmia, uncontrolled hypertension (systolic ≥ 160 or diastolic ≥ 100 mmHg on repeated measurement), congestive heart failure, or syncope of unclear cause.
    7. Untreated moderate-to-severe obstructive sleep apnea (STOP-Bang ≥ 5 without evaluation and clearance), restless legs syndrome requiring pharmacologic treatment, narcolepsy, or a circadian rhythm sleep-wake disorder.
    8. Moderate or severe substance or alcohol use disorder within the prior 6 months, or a positive urine drug screen for a non-prescribed substance judged to affect sleep or autonomic measures.
    9. Lifetime diagnosis of bipolar I disorder, schizophrenia, schizoaffective disorder, or another primary psychotic disorder.
    10. Active suicidal ideation with intent or plan (C-SSRS ideation type 4 or 5), any suicide attempt within the prior 6 months, or any clinical presentation requiring urgent or higher-level psychiatric care.
    11. Use of an alternative neuromodulation therapy (implanted VNS, transcranial magnetic stimulation, transcranial direct current stimulation, or electroconvulsive therapy) within the prior 3 months.
    12. Initiation of, or change in dose of, any medication with known substantial effects on heart rate variability (for example, beta-blockers, anticholinergics) within 6 weeks before Visit 1.
    13. Any medical, neurological, or psychiatric condition that, in the investigator's judgment, would compromise participant safety, adherence, or interpretation of study measures.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore fittizio: Sham Run-In (Weeks 1-2)

Inactive sham stimulation, twice daily. Each participant receives first.

sham run-in ctVNS

Comparatore attivo: Active stimulation (Weeks 3-6)

Blinded active cervical nVNS, twice daily. Each participant receives second.

ctVNS

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Primary physiologic endpoint as change in parasympathetic heart rate variability (nocturnal RMSSD).
Lasso di tempo: Change from Visit 2 (week 2) to Visit 3 (week 6).

Linear mixed-effects models estimating within-subject physiologic change from the end-of-sham anchor (week 2), with participant as a random effect and phase, time, cohort, age, sex, and body mass index as fixed effects.

Change from Visit 2 (week 2) to Visit 3 (week 6).
Primary clinical endpoint as change in Insomnia Sleep Index (ISI) total score in Cohort A (affected).
Lasso di tempo: Change from Visit 2 (week 2) to Visit 3 (week 6).

The ISI is a 7-item self-report questionnaire used to assess nature, severity and impact of insomnia over previous 2 weeks. Each item is rated 0-4 , with total score range of 0-28. Higher score indicates greater insomnia severity. Response is defined as ≥ 50% reduction in ISI total score or remission (ISI ≤ 7).

Change from Visit 2 (week 2) to Visit 3 (week 6).

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Montgomery-Asberg Depression Rating Scale (MADRS) total score in Cohort A (affected) from Visit 2 to Visit 3.
Lasso di tempo: Change from Visit 2 (week 2) to Visit 3 (week 6).

The MADRS is a 10-item clinician rated scale used to assess severity of depression symptoms. Each item is scored from 0 to 6, with total possible score range of 0-60. A total score of 0-8 indicates no depression, and 8 or above would indicate some level of depression ranging from mild to severe. Higher score indicates greater depression symptoms.

Change from Visit 2 (week 2) to Visit 3 (week 6).
Differential expression of neural-derived exosomal microRNAs from Visit 2 to Visit 3.
Lasso di tempo: Change from Visit 2 (week 2) to Visit 3 (week 6).

Differential expression screening with Benjamini-Hochberg false discovery rate control (q < 0.05), followed by exploratory penalized regression classifiers with nested cross-validation and reporting of optimism-corrected performance.

Change from Visit 2 (week 2) to Visit 3 (week 6).

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Matthew Macaluso, DO, University of Alabama at Birmingham

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 dicembre 2026

Completamento primario (Stimato)

30 settembre 2028

Completamento dello studio (Stimato)

1 gennaio 2029

Date di iscrizione allo studio

Primo inviato

16 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

13 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • STUDY00000060
  • TEAMSCI9617 (Altro numero di sovvenzione/finanziamento: UAB Heersink School of Medicine (Team Science Award))

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

Sì

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .